AnaCardio announces issuance of U.S. patent for AC01, strengthening protection into the 2040s
Stockholm, Sweden and Lugano, Switzerland, March 11, 2026 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that U.S. Patent No. 12,569,476 has been issued by the United […]